[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351548-105":59,"doc-detail-351548-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","patient-derived-tumor-organoids-for-new-drug-development-promises-and-challenges","Patient-derived tumor organoids for new drug development: promises and challenges","","Antitumor drug development is hindered by long R&D timelines, substantial in vivo efficacy variability, and pronounced inter-individual differences in response. Patient-derived tumor organoids (PDTOs) are presented as a three-dimensional preclinical cancer model that self-organizes from stem cells into micro-organs resembling original tumors. The review highlights PDTOs’ ability to retain biological and molecular features and preserve tumor heterogeneity, supporting drug screening, new target discovery, diagnostics, and evaluation of efficacy and toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-derived-tumor-organoids-for-new-drug-development-promises-and-challenges/351548/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-derived-tumor-organoids-for-new-drug-development-promises-and-challenges/351548.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this review address in antitumor drug development?","Question",{"text":112,"@type":113},"It addresses unfavorable factors such as long R&D cycles, large differences in in vivo drug efficacy, and differences in how individuals respond to therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do patient-derived tumor organoids (PDTOs) relate to original tumors?",{"text":117,"@type":113},"PDTOs are 3D microstructures differentiated from stem cells that self-organize into micro-organs resembling the original tumor tissues while preserving tumor heterogeneity.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are conventional preclinical models considered insufficient for drug development?",{"text":121,"@type":113},"Two-dimensional cell lines lack tumor microenvironment and spatial organization and lose tumor heterogeneity during long-term culture, while PDX models are costly, slow, have limited success rates, and are not well aligned with high-throughput screening workflows.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351548,1790195262,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Investigational New Drugs (2026) 44:90–102  \n[https://doi.org/10.1007/s10637-026-01605-3](https://doi.org/10.1007/s10637-026-01605-3)  \nPatient‑derived tumor organoids for new drug development: promisesand challenges  \nMeijun He1 · Ying Wu1 · Furong Du2 · Jingrui Wang2 · Honghan Zhang3 · Jian Han3  \nReceived: 17 October 2025 / Accepted: 27 January 2026 / Published online: 14 February 2026 © The Author(s) 2026  \nSummary  \nThe development of antitumor drugs is affected by various unfavorable factors, including long cycles of research and development, large differences in drug efficacy in vivo, and efficacy differences in individuals. Patient-derived tumor organoids (PDTOs), a novel preclinical model in cancer research, are three-dimensional microstructures differentiated from stem cells, with the capability of self-organizing into micro-organs that resemble the original tumor tissues. They have been demonstrated to faithfully recapitulate the biological and molecular features of the original tumor while preserving the tumor heterogeneity. Recently, PDTOs show great potential in drug screening and new drug development. In this review, we overviewed the types of organoids, application of PDTOs in developing new drugs, as well as their challenges and opportunities to provide powerful insights into drug development.  \nKeywords Tumor organoids · Stem cells · Drug development · Novel drug targets · Diagnostic markers  \nIntroduction  \nCancer remains a major cause of death worldwide. In 2023, 18.5 million incident cases of cancer and 10.4 million deaths were estimated, excluding non-melanoma skin cancers [1] . As a significant contributor to the global disease burden, cancer is expected to have increased incidence and mortality rates by 2050. Tumorigenesis is a complex process involving the interaction of multiple factors, and the tumor microenvironment (TME) plays a crucial role in tumor initiation, progression, and metastasis [2] . Cells in the TME can both inhibit tumor growth and support tumor  \nMeijun He and Ying Wu contributed equally to this work.  \n* Jian Han [hanjian2025@163.com](hanjian2025@163.com)  \n1 Department of Obstetrics and Gynecology, The 920th Hospital of Joint Logistics Support Force, Kunming 650032 Yunnan, China  \n2 Department of Medicine, Kingbio Medical Co., Ltd,  \n401123 Chongqing, China  \n3 Precision Medicine Center of Chuxiong Yi Autonomous Prefecture, The People’s Hospital of Chuxiong Yi Autonomous Prefecture &, The Fourth Affiliated Hospital of Dali University, No. 138 Lucheng South Road, Chuxiong Yi Autonomous Prefecture 675000, Yunnan, China  \nprogression [3] . Tumor-suppressive cells can recognize and eliminate cancer cells, thereby boosting therapeutic efficacy. In contrast, tumor-promoting cells create an immunosuppressive microenvironment that allows cancer cells to escape immune surveillance, fosters tumor proliferation and invasion, reduces drug penetration, and ultimately leads to drug resistance [4]. In addition to the TME, tumor heterogeneity, defined as the molecular or genetic variations that arise in tumor daughter cells after repeated division and proliferation during tumor growth, is also a key factor affecting drug response and resistance in cancer treatment [5] . Owing to tumor heterogeneity, patients with the same type of cancer may experience significantly divergent therapeutic responses to the same anticancer drug [6] . The dynamic interactions between cancer cells and the TME and the presence of tumor heterogeneity underscore the pressing requirement for the establishment of preclinical models that can accurately predict drug response and resistance.  \nIt is reported that the major cause for phase II and phase III failures during 2013–2015 is lack of efficacy and safety, and the correlation between preclinical models and clinical practice is low [7] . Conventional drug screening mainly depends on two-dimensional cancer cell lines and patient-derived tumor xenograft (PDX) models, which u","cbCait97Gyg9ZlVA","https://ap.wps.com/l/cbCait97Gyg9ZlVA","pdf",2050361,13,"English","# Summary\n# Introduction\n## Cancer burden and tumor heterogeneity\n## Tumor microenvironment and drug resistance\n## Limits of conventional models (cell lines, PDX)\n# Types of organoids\n# Applications of PDTOs in new drug development\n## Drug screening and novel targets\n## Biomarkers and prognostic markers\n## Assessing efficacy and toxicity","[{\"question\":\"What problem does this review address in antitumor drug development?\",\"answer\":\"It addresses unfavorable factors such as long R\\u0026D cycles, large differences in in vivo drug efficacy, and differences in how individuals respond to therapy.\"},{\"question\":\"How do patient-derived tumor organoids (PDTOs) relate to original tumors?\",\"answer\":\"PDTOs are 3D microstructures differentiated from stem cells that self-organize into micro-organs resembling the original tumor tissues while preserving tumor heterogeneity.\"},{\"question\":\"Why are conventional preclinical models considered insufficient for drug development?\",\"answer\":\"Two-dimensional cell lines lack tumor microenvironment and spatial organization and lose tumor heterogeneity during long-term culture, while PDX models are costly, slow, have limited success rates, and are not well aligned with high-throughput screening workflows.\"}]","Patient-derived tumor organoids for new drug development: promises and challenges | PDF",1790094662,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfcc63fe1b2d952a5a63774f4990d9dc.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f947d0a95581ea5db41e4af65bab353d.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/425858d19e14629d1f7ea93d7e9816cc.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3fd8c2e914dc710164cc1f7dbb62d64d.webp",980,1301]